{
    "Trade/Device Name(s)": [
        "BioSieveTM Multi-Drug Urine Test Panel",
        "BioSieveTM Multi-Drug Urine Test Panel Rx"
    ],
    "Submitter Information": "VivaChek Biotech (Hangzhou) Co., Ltd.",
    "510(k) Number": "K233062",
    "Predicate Device Reference 510(k) Number(s)": [
        "K202567"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NFT",
        "NFY",
        "NGL",
        "PTH",
        "NFV",
        "PTG",
        "NGG",
        "LCM",
        "QBF",
        "QAW",
        "NFW"
    ],
    "Summary Letter Date": "September 21, 2023",
    "Summary Letter Received Date": "September 26, 2023",
    "Submission Date": "October 25, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.3100",
        "21 CFR 862.3650",
        "21 CFR 862.3150",
        "21 CFR 862.3170",
        "21 CFR 862.3250",
        "21 CFR 862.3620",
        "21 CFR 862.3610",
        "21 CFR 862.3700",
        "21 CFR 862.3910",
        "21 CFR 862.3870"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system",
        "Opiate test system",
        "Barbiturate test system",
        "Benzodiazepine test system",
        "Cocaine test system",
        "Methadone test system",
        "Methamphetamine test system",
        "Propoxyphene test system",
        "Tricyclic antidepressant drugs test system",
        "Cannabinoids test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Buprenorphine",
        "Secobarbital",
        "Oxazepam",
        "Cocaine",
        "2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine",
        "Methamphetamine",
        "Methylenedioxymethamphetamine",
        "Morphine",
        "Methadone",
        "Oxycodone",
        "Phencyclidine",
        "Propoxyphene",
        "Nortriptyline",
        "Marijuana",
        "Cannabinoids"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        ""
    ],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunochromatographic assay",
        "Competitive binding immunoassay"
    ],
    "Methodologies": [
        "Lateral flow immunoassay",
        "Immunochromatography",
        "Competitive binding"
    ],
    "Submission Type(s)": [
        "Panel",
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for BioSieveTM Multi-Drug Urine Test Panel and BioSieveTM Multi-Drug Urine Test Panel Rx, lateral flow immunoassays for qualitative urine detection of multiple drugs of abuse.",
    "Indications for Use Summary": "Qualitative and simultaneous detection of up to 15 drugs of abuse (e.g., amphetamine, cocaine, marijuana, opioids, benzodiazepines, etc.) in human urine at specified cutoff concentrations; intended for in vitro diagnostic use, OTC and prescription.",
    "fda_folder": "Toxicology"
}